About On the Frontlines of Non-Small Cell Lung Cancer
Catch up on the latest updates on non-small cell lung cancer treatment from the 2024 American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, and the European Society for Medical Oncology Congress in this exclusive conference coverage series.
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Doctors Elaine Shum and Estelamari Rodriguez discuss with host Dr. Jacob Sands the pooled analysis of Dato-DXd for EGFR-mutated advanced non-small cell lung cancer, highlighting its efficacy and manageable safety profile in this interview.
2 Jan 2025
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Host: Jacob Sands, MD
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.
31 Dec 2024
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laura Alder, MD
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.
23 Dec 2024
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.
23 Dec 2024
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.
23 Dec 2024
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Host: Jacob Sands, MD
Guest: Alex Spira, MD, PhD, FACP
Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study’s design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.
23 Dec 2024
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Thomas Egenod, MD
In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.
13 Dec 2024
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Dr. Marina Garassino and Dr. Jacob Sands discuss how a TROP2 biomarker may predict patient response to Dato-DXd, a potential game-changer for advanced NSCLC treatment.
9 Sept 2024
Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua E. Reuss, MD
The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.
27 Aug 2024
Poster Pearl: Dato-DXd Demonstrates Intracranial Efficacy in NSCLC
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Podcast Authority Score: 3 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
5
Social presence
0
YouTube
0
Engagement
0
Contact On the Frontlines of Non-Small Cell Lung Cancer
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of On the Frontlines of Non-Small Cell Lung Cancer?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
